Mengyao Wang

Title: Innovations of Mengyao Wang in Chimeric Antigen Receptor Technology

Introduction

Mengyao Wang is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of biotherapeutics, particularly in the development of chimeric antigen receptor (CAR) cells. His innovative work focuses on targeting specific proteins associated with tumors, which has the potential to revolutionize cancer treatment.

Latest Patents

Mengyao Wang holds a patent for "Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof." This patent describes a CAR cell that specifically targets human Claudin18.2 (CLDN18A2). The invention includes a preparation method and applications for treating tumors. The CAR's extracellular binding region comprises a protein that recognizes CLDN18A2, utilizing amino acid sequences with high identity to those specified in the patent. This advancement in CAR technology represents a promising approach to cancer immunotherapy.

Career Highlights

Mengyao Wang is associated with Nanjing Kaedi Biotherapeutics Ltd., where he continues to develop innovative therapeutic solutions. His work has garnered attention in the scientific community, contributing to advancements in cancer treatment methodologies. His dedication to research and development has positioned him as a key figure in the biotherapeutics industry.

Collaborations

Mengyao Wang collaborates with talented colleagues, including Hui Xu and Jingjing Zhu. Their combined expertise enhances the research and development efforts at Nanjing Kaedi Biotherapeutics Ltd.

Conclusion

Mengyao Wang's contributions to the field of chimeric antigen receptor technology highlight his innovative spirit and commitment to advancing cancer treatment. His patent on targeting CLDN18A2 represents a significant step forward in immunotherapy, showcasing the potential of CAR cells in clinical applications.